Glycated albumin, measured in the third trimester, emerges as a significant predictor for multiple adverse outcomes, including neonatal hypocalcemia, polycythemia, respiratory disorders, and myocardial hypertrophy. This evidence concerns the gene ALB and cardiac hypertrophy.